Zobrazeno 1 - 10 of 33 pro vyhledávání: '"Anna Cruceta"'
1
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study
Autor: Javier Murillas, M. Cervantes, José Mallolas, S. López-Calvo, Josep M. Guardiola, Montserrat Laguno, Jordi Navarro, Carmen Cifuentes, Anna Cruceta, Ana Carrero, M.A. Von Wichmann, Juan A. Pineda, María Martínez-Rebollar, Elisabeth Deig, J.L. Gómez-Sirvent, Antoni Jou, E. Van den Eynde, A. Tapiz, Marisa Montes, J.D. Ruiz-Mesa, S. Veloso, E de Lazzari
Publikováno v: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
International Journal of Infectious Diseases, Vol 53, Iss C, Pp 46-51 (2016)
Dipòsit Digital de la UB
Universidad de Barcelona
Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-alpha 2a/ribavirin (PEG-IFN/RBV) in the retreatment
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a02d557208f7cecc8a3022e84c4e80f
http://hdl.handle.net/2445/160558
Zobrazit plný text záznamu
2
Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus Atazanavir Each with Zidovudine/Lamivudine
Autor: Anna Cruceta, Joan Albert Arnaiz, David Dalmau, Pere Domingo, Vicens Díaz-Brito, Bonaventura Clotet, Felipe García, Josep M. Gatell, Joaquim Peraire, Agathe León, Hernando Knobel
Publikováno v: ANTIVIRAL THERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background A clinical trial comparing the rate of discontinuation and tolerability of two post-exposure prophylaxis (PEP) regimens was performed. Methods A total of 255 individuals attending the emergency rooms of six hospitals for exposure to HIV an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0494940a96e69bb8df124a26532ee07e
https://doi.org/10.3851/imp1955
Zobrazit plný text záznamu
3
A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients
Autor: David Dalmau, J. Flores, Anna Cruceta, J. Mallolas, Miró Jm, Francesc Vidal, José Luis Santiago Blanco, A. Ochoa, Esteban Martínez, José Peña, E. de Lazzaria, J.A. Arnaiz, M.A. Ribas, Enric Pedrol, Judit Pich, S. Varea, José M. Gatell, Ferran Segura
Publikováno v: Revista Clínica Española. 207:427-432
Background The use of HAART combining 2 nucleoside analogues reverse transcriptase inhibitors (NRTIs) plus one protease inhibitor (PI) or 2 NRTIs + 1 non-nucleoside reverse transcriptase inhibitor (NNRTI) has shown comparable efficacy. The study was
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::614a8810e2dfcfa847396aa66d8466b2
https://doi.org/10.1157/13109831
Zobrazit plný text záznamu
4
Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir
Autor: Arkaitz Imaz, Iñaki Perez, Jhon Rojas, Esteban Martínez, Vicente Estrada, Montserrat Lonca, Marta Montero, Victor Asensi, Joan Fontdevila, L. Del Rio, Celia Miralles, Anna Cruceta, Gatell Jm, Mireia Arnedo, Pere Domingo
Publikováno v: HIV MEDICINE
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Objective To assess whether changes in antiretroviral drugs other than thymidine nucleoside reverse transcriptase inhibitors (NRTI) may have a body fat impact in HIV-infected patients with lipoatrophy. Methods Ninety-six-week phase IV, open-label, mu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5d7df597b43699763a6ef23c46f3b7e
https://pubmed.ncbi.nlm.nih.gov/27089862
Zobrazit plný text záznamu
5
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial)
Autor: Jose M, Miro, Christian, Manzardo, Elena, Ferrer, Montserrat, Loncà, Alberto C, Guardo, Daniel, Podzamczer, Pere, Domingo, Adrian, Curran, Bonaventura, Clotet, Anna, Cruceta, Francisco, Lozano, Iñaki, Pérez, Montserrat, Plana, Jose M, Gatell
Publikováno v: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background: Few randomized clinical trials have investigated antiretroviral regimens in very advanced HIV-1-infected patients. The objective was to study the immune reconstitution in very immunosuppressed antiretroviral-naive, HIV-1-infected individu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0a1450b0b10074afe720de5313d74e8
https://pubmed.ncbi.nlm.nih.gov/25831464
Zobrazit plný text záznamu
6
Relevance of HIV-1-Specific CD4+ Helper T-Cell Responses During Structured Treatment Interruptions in Patients With CD4+ T-Cell Nadir Above 400/mm3
Autor: Catherine Fagard, Anna López, Felipe García, Ferran Segura, Tomás Pumarola, Anna Cruceta, Gabriel M. Ortiz, Teresa Gallart, Lucia Lopalcos, Annette Oxenius, Rodney E. Phillips, José M. Gatell, Maria A. Sambeat, José M. Miró, Mireia Arnedo, Gabriel Mestre, Emilio Fumero, Bernard Hirschel, Douglas F. Nixon, Montserrat Plana
Publikováno v: Journal of Acquired Immune Deficiency Syndromes, Vol. 36, No 3 (2004) pp. 791-799
OBJECTIVES: To analyze the dynamics of both HIV-1-specific CD4 and CD8 T-cell responses during structured treatment interruptions (STIs) in chronically HIV-1-infected (CHI) patients and to correlate them with the viral set point achieved. METHODS: Fo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8614a748ca8fc693697bb64e05dd70a1
https://doi.org/10.1097/00126334-200407010-00005
Zobrazit plný text záznamu
7
Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection
Autor: Mireia Arnedo, José M. Miró, Teresa Gallart, José M. Gatell, Anna Cruceta, Cristina Gil, Tomás Pumarola, Felipe García, Montserrat Plana, Gabriel Mestre
Publikováno v: AIDS. 16:1761-1765
Background: The objective was to analyse which baseline factors could predict a favourable outcome after structured therapy interruption (STI). Methods: Data of three Spanish pilot studies of STI in early stage chronic HIV-1-infected patients were an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26e0176dda3c6dbc917b569a1545650c
https://doi.org/10.1097/00002030-200209060-00008
Zobrazit plný text záznamu
8
Immunological function restoration with Lopinavir/ritonavir vs Efavirenz containing regimens in HIV infected patients: a randomized clinical trial
Autor: Bonaventura Clotet, Marcelo Sánchez, Esteban Martínez, Alba Díaz, Lorna Leal, José M. Benito, Llucia Alos, José M. Gatell, Eugenia Negredo, Norma Rallón, Joan Albert Arnaiz, Felipe García, Anna Cruceta, Montserrat Lonca, Agathe León, Berta Torres, Constanza Lucero
Publikováno v: Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
CD4(+) count increase has been reported to be different with lopinavir/r (LPV/r) and efavirenz (EFV)-containing regimens. The different effect of these two regimens on other immune function parameters and the relationship with the gain of CD4(+) coun
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deda1de83647ecc0df3c870c52e3debf
http://hdl.handle.net/2445/106786
Zobrazit plný text záznamu
9
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
Autor: Jose M. Gatell, Esteban Martínez, Josep Mallolas, Amanda Mocroft, Xavier Carné, Miguel A. Garcia-Viejo, Ana Milinkovic, José L. Blanco, Anna Cruceta, José B. Perez-Cuevas, J.A. Arnaiz, Maria Angeles Marcos, Andrew N. Phillips
Publikováno v: AIDS. 15:1261-1268
Objectives: To assess the incidence and risk factors for hepatotoxicity associated with nevirapine.Design: A prospective cohort study in a teaching and referral hospital involving all consecutive patients who were prescribed a nevirapine-containing a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cae6c793b166a8a580e18dc5bb3f1dc
https://doi.org/10.1097/00002030-200107060-00007
Zobrazit plný text záznamu
10
Dose-Finding Study of Once-Daily Indinavir/Ritonavir Plus Zidovudine and Lamivudine in HIV-Infected Patients
Autor: M. Sarasa, José L. Blanco, Tomás Pumarola, Carles Codina, Esteban Martínez, Alex Soriano, Josep M. Gatell, Anna Cruceta, Josep Mallolas, Xavier Carné, Vicenc Giner, Joan Albert Arnaiz, Miguel A. Garcia-Viejo, Dolors Soy, Montse Tuset
Publikováno v: Scopus-Elsevier
Background: Strategies for treatment of HIV need to be considered in terms of combining potency, safety, and convenience of dosage. However, regimens including once-daily protease inhibitors are not yet available. We have performed a pilot study to d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40ece7ef639b32a9c9604f17a7f3e434
https://doi.org/10.1097/00126334-200011010-00004
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje